Almac has added an Xcelodose 600S precision powder micro-dosing system to its product development capabilities.
The addition is in response to client requirements for preclinical and early phase clinical GMP supply.
For simple formulations of API or powder-in-capsule, the Xcelodose system is said to significantly reduce processing time and API usage, resulting in cost savings when compared with hand-filling options.
Complementing Almac's existing containment capabilities for processing compounds with an OEL ranging from 0.03-10ug/m3/8hrs TWA, the Xcelodose 600S system will include an Xcelohood system to offer containment when filing capsules with API of high or unknown toxicity.
The Xcelodose system, manufactured by Capsugel, is a precision powder micro-doser and automated encapsulator that has the ability to fill formulations or API directly into capsules with a high level of accuracy.
It can dispense amounts as low as 100 micrograms and up to 100 milligrams and beyond, into capsules from size 00 to 4.
Dosing directly into capsules can reduce the amount of API required.
Additionally, the unit minimises overall development time by simplifying analytical and stability protocols.
Almac will install the Xcelodose system in its product development facility in Craigavon, UK.
It will be ready for use from March 2010.
